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Abstract
Background: High Human Immunodeficiency Virus (HIV) prevalence and high risk behaviors have been well
documented within United States (US) correctional systems. However, uncertainty remains regarding the extent to
which placing people in prison or jail increases their risk of HIV infection, and regarding which inmate populations
experience an increased incidence of HIV. Describing these dynamics more clearly is essential to understanding
how inmates and former detainees may be a source for further spread of HIV to the general US population.
Methods: The authors conducted a systematic review and meta-analysis of studies describing HIV incidence in US
correctional facility residents and, for comparison, in high risk groups for HIV infection, such as non-incarcerated
intravenous drug users (IVDU) and men who have sex with men (MSM) in the US. HIV incidence rates were further
compared with Hepatitis B and Hepatitis C Virus rates in these same populations.
Results: Thirty-six predominantly prospective cohort studies were included. Across all infection outcomes,
continuously incarcerated inmates and treatment recruited IVDU showed the lowest incidence, while MSM and
street recruited IVDU showed the highest. HIV incidence was highest among inmates released and re-incarcerated.
Possible sources of heterogeneity identified among HIV studies were risk population and race.
Conclusions: Although important literature gaps were found, current evidence suggests that policies and
interventions for HIV prevention in correctional populations should prioritize curtailing risk of infection during the
post-release period. Future research should evaluate HIV incidence rates in inmate populations, accounting for
proportion of high risk sub-groups.
Background
In 2008, nearly 2.4 million people were incarcerated in
United States (US) jails or prisons [1,2]. Furthermore,
about 25% of persons living with the Human Immuno-
deficiency virus (HIV) and about 30% of those living
with Hepatitis C Virus (HCV) infection spent time in
correctional facilities [3]. As a result, many have
expressed concerns that transmission of blood-borne
infections among inmates may be a major source for
further spread to the general population [4-7].
Three lines of evidence support this view: (1) the pre-
valence of HIV infection, viral hepatitis, and sexually-
transmitted infections (STI) is typically higher in
incarcerated than in non-incarcerated populations;
(2) illicit drug injection, unprotected sexual activity, and
other risky behaviors are common in prisons and jails;
and (3) correlative studies have repeatedly found inde-
pendent associations between antecedents of incarcera-
tion and increased risk for infections such as HIV.
In more details, despite declines since the 1990s, it has
been estimated in 2008 that 1.5% of the total US cus-
tody population in federal and state prisons was infected
with HIV [8]; that 12.0% to 35.0% had chronic HCV
infection [3]; and that 1.0% to 3.7% had serological mar-
kers of chronic HBV infection [3]. Based on these esti-
mates, the prevalence of HIV was about four times
higher among prison inmates than in the general popu-
lation [9]. Likewise, the prevalence of chronic HBV
infection was 2 to 6 times higher, and that of chronic
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inmates than in the community.
In contrast, more uncertainty remains about the
extent of high-risk behavior taking place within US cor-
rectional facilities. Due to important differences between
institutions in enabling factors such as overcrowding
and understaffing, estimates of interest vary widely.
Recent studies suggest that 3.0% to 28.0% of adult
inmates use intravenous drugs while incarcerated; 4.0%
to 65.0% engage in unprotected homosexual activities
[3,10,11]; and 0.0% to 15.7% report sexual victimization
during incarceration [12]. Prison entrants, incarcerated
inmates, and intravenous drug users (IVDU) also tend
to share a number of incarceration-related factors that
predict HIV infection, including overall length of time
spent incarcerated [13], repeated incarceration [14], tat-
tooing in prison [15-17], and history of syringe sharing
in prison [18-20]. Comparable observations have been
made for other blood-borne infections and STI
[14,21-26].
As just discussed, high HIVp r e v a l e n c ea n dh i g hr i s k
behavior within correctional systems are well documen-
ted. There is much less evidence, however, to support
the notion that the correctional setting increases the
incidence of HIV, and thus plays a central role in sus-
taining or increasing community rates when inmates are
released. Many investigators, in fact, have suggested that
inmates appear more likely to acquire infection outside
than inside correctional facilities [3,10,27]. Since deter-
mining the role of incarceration in the epidemiology of
HIV transmission is a crucial step toward formulating
cost-effective public health policies and interventions for
US HIV/AIDS control, we conducted a systematic and
comparative literature review of HIV, HBV, and HCV
incidence among residents of correctional facilities,
released detainees, community-living IVDU and com-
munity-living men who have sex with men (MSM) in
t h eU S .O u ra i m sw e r et w o f o l d :t os u m m a r i z et h ep u b -
lished literature on HIV incidence rates and other key
blood-borne infections, such as HBV and HCV, in US
correctional facilities; and to compare these with infec-
tion rates among non-incarcerated individuals who bear
high burdens of blood-borne infections and STIs. We
hypothesized that inmates experience a lower incidence
of HIV than community living risk groups that practice
the behaviors which place incarcerated populations at
increased risk. We further postulated that comparisons
between viruses that share the same routes of transmis-
sion in prisons, jails, and high risk groups in the com-
munity will provide the comparative basis to more
clearly elucidate the role the correctional setting may
play in increased risk of infection and the likely avenues
for further spread to the community.
Methods
Search Strategy and Selection Criteria
The authors searched Medline/PubMed, PsycINFO/Ebs-
coHost and Embase/Scopus (January 1990 to September
2009) for English language studies conducted in the US.
Medline searches used permutations of medical subject
headings (MeSH) and subheadings for each risk group
and infection outcome of interest. In Embase, searches
were developed using Emtrees and author defined key-
words for relevant articles identified through the Med-
line searches. The same keyword strategy was used with
PsycINFO (Table 1). References of all review articles
identified in the search [3,7,10,27-32] and of all articles
selected for full review were hand-searched for addi-
tional studies. All search strings were developed with
the assistance of a qualified librarian.
Two investigators (EG and LG) independently assessed
titles and abstracts to identify original research studies
eligible for review. If eligibility could not be determined
from reviewing titles and abstracts, the full article was
retrieved. An article was chosen if it reported an inci-
dence density (or cumulative incidence per year at risk)
for one or more infections of interest (HIV, HBV, HCV)
among inmates (incarcerated, released, reincarcerated),
non-incarcerated high-risk individuals (MSM, IVDU) or
both. Articles that did not provide original data, case
reports, legal cases, case-control studies, and reports of
outbreak investigations were excluded. We also excluded
estimates of infection incidence measured among indivi-
duals entering the prison system for the first time, since
these individuals had not been exposed to the correc-
tional environment yet and, therefore, were representa-
tive of their community of origin rather than of the
inmate population.
Data Abstraction
Once eligibility was determined, two reviewers (EG and
MM) independently extracted data from selected articles
using a standardized checklist. Discrepancies were cor-
rected by consensus. For each infection and population
of interest, the following information was retrieved: sam-
ple characteristics (age, sex and race composition, num-
ber of subjects at risk, and prevalence of infection at
baseline), risk behaviors (same sex risk behaviors, intrave-
nous drug use), number of infections during follow-up,
length of follow-up, and attrition rate. Information on
study characteristics was also collected (study period, site
of data collection, study design, diagnostic methods, and
study limitations). Depending on data availability, data on
demographic characteristics and risk behavior described
either the total sample tested at baseline or the baseline
seronegative sample. Corresponding authors were con-
tacted by email for data of interest not published in the
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responded with the data requested, 27.0% (9/34)
responded saying that data were no longer available, and
the remainder did not respond. When multiple publica-
tions reported on the same study cohort, we used the
most recent and complete data.
Operational definitions
Baseline prevalence of infection was defined as the per-
centage of subjects who tested positive for infection at
baseline; incidence density of infection as the average
number of new infections in baseline seronegative sub-
jects per 100 person-years (py) of follow-up; cumulative
incidence of infection as the percentage of subjects diag-
nosed with a new infection among baseline seronegative
subjects who had ≥1f o l l o w - u pt e s t ;attrition rate as the
percentage of baseline seronegative subjects who did not
undergo ≥1 follow-up; and predominant race (sex)a st h e
ethnic or racial group (sex) that comprised the majority
of study subjects. Continuously incarcerated inmate
populations (CIIP) were defined as cohorts of inmates
tested at entry, or post entry, with follow-up after at least
12 months of incarceration. There was one exception in
which inmates were tested at entry or post entry, with
follow-up testing at exit, regardless of the duration of
their incarceration [33]. Inmates released and reincarcer-
ated (IRAR) were defined as cohorts of inmates with at
least two incarcerations during the study period who
were tested at each intake, booking, or time of incarcera-
tion, with the exception of one study in which the
authors described the cohort as “reincarcerated” [34].
Statistical analysis
Where person-years of follow-up and median follow-up
time were reported neither by the article nor by the
contacted author, we estimated total person-years
accrued from the reported incidence per 100py and the
total number of new infections (13 articles). For two
Table 1 Search Strategies
Search
#
Medline PsychInfo Scopus
1 (prisons OR prisoners) AND (HIV infections/
transmission OR HIV infections/epidemiology
OR HIV infections/prevention and control)
(human immunodeficiency virus OR
acquired immune deficiency syndrome)
AND (prisoners OR prisons)
HIV AND prison* AND transmission
2 (prisons OR prisoners) AND (substance abuse,
intravenous OR needle sharing OR tattooing)
(incarceration OR institutional schools OR
maximum security facilities OR correctional
institutions OR prisons OR reformatories)
AND (human immunodeficiency virus OR
acquired immune deficiency syndrome)
HIV and (prison* OR inmate*) AND (injection
drug OR intravenous drug)
3 (prisons OR prisoners) AND (hepatitis c OR
hepatitis c virus OR hepatitis b OR hepatitis b
virus)
1 AND (cohort analysis OR longitudinal
studies) AND male homosexuality
(hepatitis c OR hepatitis B) AND (incidence OR
epidemiology OR cohort) AND (United States)
AND (homosexual* W/3 male OR men who
have sex with men)
4 3 AND homosexuality (intravenous drug usage OR needle sharing)
AND (cohort analysis OR longitudinal
studies) AND male homosexuality
(incidence OR epidemiology OR cohort) AND
(United States) AND (needle W/3 sharing OR
intravenous W/5 substance *use* OR
intravenous W/5 drug *use* OR ivdu) AND
(hepatitis c OR hepatitis b)
5 (HIV infections/transmission OR HIV
infections/epidemiology) AND (incidence OR
cohort studies) AND (United States) AND
(homosexuality, male)
(male homosexuality AND (epidemiology
OR cohort analysis OR longitudinal studies)
AND (hepatitis)
(hiv OR aids OR human immunodeficiency
virus OR acquired immune deficiency
syndrome) AND (incidence OR epidemiology
OR cohort) AND (United States) AND (needle
W/3 sharing OR intravenous W/5 substance
*use*) OR intravenous W/5 drug *use* OR
ivdu)
6 5 (NOT homosexuality, male) AND (substance
abuse, intravenous OR needle sharing)
(intravenous drug usage OR needle sharing)
AND (epidemiology OR cohort analysis OR
longitudinal studies) AND (hepatitis)
(United States) AND (incidence OR cohort OR
epidemiology) AND (hiv OR aids OR human
immunodeficiency virus OR acquired immune
deficiency syndrome) AND (homosexual* W/5
male OR men have sex with men)
7 (hepatitis c OR hepatitis c virus OR hepatitis
b OR hepatitis b virus) AND (homosexuality,
male) AND (United States) AND (incidence
OR cohort studies OR epidemiology)
8 7 (NOT homosexuality, male) AND (substance
abuse, intravenous OR needle sharing)
Search terms used during the literature search are reproduced here. Each search was numbered, and numbers indicate where searches were combined to create
more specific search criteria. Abbreviations: HIV, Human Immunodeficiency Virus.
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data on cumulative incidence and median follow-up
time. To ensure comparability of confidence limits
across studies regardless of sample size, 95% confidence
intervals (95%CI) were recalculated for all incidence
density estimates using the exact Poisson method [37].
Due to significant heterogeneity among studies demon-
strated in a fixed effects model, pooled estimates of inci-
dence density and 95%CI were obtained for each
infection and population of interest using the DerSimo-
nian-Laird random effects method [38]. Where the num-
ber of incident cases was zero, a value of 0.5 was assigned
in order to estimate standard error for pooled incidence.
Heterogeneity among studies was assessed using the I
2
statistic, which estimates the proportion of total variation
that is due to heterogeneity beyond chance [39]. Publica-
tion bias was assessed using Egger’s test [40].
For each infection of interest, we calculated separate
pooled estimates for HIV, HBV and HCV incidence
among continuously incarcerated inmates and inmates
released and re-incarcerated. Similarly, we calculated
separate pooled incidence estimates for IVDU recruited
through street outreach, IVDU recruited from drug treat-
ment programs or clinics, IVDU recruited using either
approach, and all categories of IVDU combined. To
explore potential sources of heterogeneity, we conducted
a random-effects meta-regression analysis of HIV studies
only (the number of published estimates of HCV and
HBV incidence was too small to warrant separate meta-
regression analyses). The potential sources of inter-study
variability were defined a priori and included: sample
size, risk population, percent IVDU, percent MSM, mean
age, predominant race and sex, geographic location, attri-
tion rate, baseline prevalence, person years of follow-up,
and study start year. We also defined potential study
design characteristics that could be sources of heteroge-
neity or bias as suggested by the MOOSE statement [41].
These included publication year and follow-up design
(prospective or retrospective). Finally, we included
whether authors had been contacted for unpublished
data, and whether they responded, as two proxy variables
for the completeness and availability of study data.
A sensitivity analysis was conducted to determine the
robustness of HIV incidence results to the inclusion/
exclusion of studies that provided incomplete or impre-
cise HIV incidence data. All analyses were conducted
using SAS version 9.2 (SAS Institute, Cary, NC)
and Microsoft Excel XP (Microsoft Corp., Redmond,
Washington, USA).
Results
Literature Review
The electronic search identified 4,272 titles, of which
4,172 were excluded based on review of titles and
abstracts (Figure 1). Full text was retrieved for the
remaining 100. A backward search of references identi-
fied 26 additional titles resulting in 126 articles selected
for full review. Of these, 72 were excluded based on
study eligibility criteria and an additional 18 were
excluded because they provided insufficient information
to calculate exact 95%CI and standard errors for meta-
analysis [42-47]; did not report annualized incidence or
median follow-up time [48-54]; provided potentially
biased estimates of HIV incidence based on a self-
reported date of last seronegative test [55-58]; or calcu-
lated incidence estimates using a mathematical model
[58]. Additionally, data from two locations (Los Angeles
and San Jose, California) from one multisite study were
excluded because insufficient information was provided
to calculate standard errors for meta-analysis [34].
Study Characteristics
In total 36 unique studies were included in the meta-
analysis (Additional file 1) [33-36,60-91]. Numerical data
of interest were often difficult to locate (median Kappa
statistic of agreement among reviewers for identification
of six key variables, 0.46). In contrast, inter-rater agree-
ment on abstracted data was high once the information
was found (median intra-class coefficient of 1.0 for same
six key variables). Of the 36 studies, 10 reported an inci-
d e n c ef r o mm o r et h a no n eg e o g r a p h i cl o c a t i o n
[34,64,69-71,75,77,78,81,82]. Four studies reported one
or more incidence estimates for continuously incarcer-
ated inmates [34,35,60,83], four for inmates released
and reincarcerated [34,36,61,62], 23 for IVDU
[34,63-76,84-91], and six for MSM [77-82]. Together,
these studies yielded 53 estimates of HIV incidence, 10
estimates of HCV incidence, and 6 estimates of HBV
incidence (Figure 1). For HIV, data were found on 2 ser-
oconversions in 1,901py of follow-up among continu-
ously incarcerated inmates, 101 seroconversions in
5,253py of follow-up among inmates released and rein-
carcerated, 650 seroconversions in 37,137py among
IVDU, and 777 in 33,096py among MSM. HCV studies
reported 4 seroconversions in 733py among continu-
ously incarcerated inmates and 305 seroconversions in
2,544py among IVDU. Finally, HBV studies reported 33
seroconversions in 1,970py of follow-up among continu-
ously incarcerated inmates, and 153 seroconversions in
1,193py among IVDU.
The majority of studies reviewed were prospective
cohort studies (86.1%) (Additional file 1). Retrospective
studies included cohorts of inmates with stored speci-
mens from testing at admission [61,62,83], and cohorts
of IVDU with stored specimens from repeat testing at
drug treatment clinics [75,76]. Inmate and MSM cohorts
were predominantly white (40.4%-85.8%), while IVDU
cohorts were predominantly African American (41.0%-
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Pubmed: 1,389 (prison), 907 (MSM), 481 (IVDU)
PsycINFO: 455 (prison), 62 (MSM), 374 (IVDU)
Scopus: 391 (prison), 148 (MSM), 65 (IVDU)
Agreed by 2 reviewers for full review (100 Titles)
Selected for meta-analysis 
(54 Titles)
Excluded from meta-analysis with reason
(18 Titles)
MSM
N=  6
n = 21
Excluded with reason (72 Titles)
x No incidence or wrong outcome (28 Titles)
x Prison entrants (7 Titles)
x Poorly defined risk group (20 Titles)
x Same cohort as another study (6 Titles)
x Wrong study design (11 Titles)
Excluded after review of titles and abstracts 
(4,172 Titles)
Backward search of bibliographies 
(26 Titles)
IVDU
N = 22
n = 39
IRAR
N=  4
n = 4
a
CIIP
N=  4
n = 6
HIV
N=  6
n = 21
HIV
N = 14
b
n =2 6
HBV
N=  3
b
n=4
HCV
N=  7
b
n = 8
HIV
N=  4
n = 4 HIV
N=  2
b
n = 2
HBV
N=  2
b
n = 2
HCV
N=  2
b
n=2
Full review (126 Titles)
Figure 1 Flow Diagram of Study Selection. CIIP, continuously incarcerated inmate population; IRAR, inmates released and reincarcerated; IVDU,
intravenous drug users; MSM, men who have sex with men; N, number of articles included in the meta-analysis; n, number of incidence
estimates included in the meta-analysis;
aThe number of articles and incidence estimates do not add up because one IVDU title included an
IRAR site;
bThe number of articles included for each outcome do not add up to the total number of articles in each risk group because three
titles included >1 outcome.
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Page 5 of 1493.3%) (Additional file 2). Cohorts of continuously incar-
cerated inmates included 94.0%-100.0% of men, whereas
cohorts of inmates released and reincarcerated were
composed of either men [36] or women [34,61,62] exclu-
sively; cohorts of IVDU included 50.0% to 80.0% of men.
For all infection outcomes and populations, the modal
start year for data collection was 1994 (range 1984 to
2000). Most inmate studies began data collection in
1985 (range 1985 to 2000), while most IVDU and MSM
studies began data collection later, i.e., in 1994 (range
1985 to 2000) and 1995 (range 1984 to 1999) respec-
tively (Additional file 2).
Mean HIV baseline prevalence was 2.1% in continu-
ously incarcerated inmates (n = 2), 6.4% in inmates
released and reincarcerated (n = 4), 18.5% among all
IVDU studies (n = 16), and 6.1% among MSM studies
(n = 1). HCV baseline prevalence was 30.6% among con-
tinuously incarcerated inmates (n = 2) and 52.4% among
all IVDU studies (n = 8). Finally, HBV baseline preva-
lence was 20.3% among continuously incarcerated
inmates (n = 2) and 26.7% among all IVDU studies (n =
2) (Additional file 2).
The mean attrition rate was calculated to be 26.4%
across all infection outcomes and risk populations. In
inmate populations, the mean attrition rate was 19.0%
(n = 6); among all IVDU studies it was 40.0% (n = 31),
and among MSM studies it was 4.5% (n = 17) (Addi-
tional file 2).
In CIIP cohorts, the period of incarceration was at
least 12 months [35,60,83], with one study reporting 8.5
years as the median [35]. Horsburgh et al. reported the
incarceration period for the 2 seroconverters identified
only (20 and 130 days) [33]. In IRAR cohorts, the peri-
ods of incarceration before release were reported as a
mean of 4 days [61], mean 62 days [62], as “days follow-
ing their arrest” [34], or were not reported [36]. The
periods between incarcerations on the other hand were
reported as a median of 316 days [36], median of 527
days [62], or were not reported [34,61].
Overall, the most common limitation reported across
all risk groups and infections of interest was limited
generalizability of study results due to non-random sam-
pling methodology or differential loss to follow-up
(Additional file 1).
Meta-analysis
The pooled estimate of HIV incidence density was low-
est among continuously incarcerated inmates (0.08/
100py, 95%CI:0.0,0.24), followed by a more than 10-fold
higher incidence for IVDU populations recruited from
treatment programs (1.14/100py, 95%CI: 0.83,1.45), and
highest among MSM (2.12/100py, 95%CI:1.82,2.42),
street recruited IVDU (2.78/100py, 95%CI:2.24,3.32),
and inmates released and reincarcerated (2.92/100py,
95%CI:2.02,3.82). Comparison of the 95%CIs suggested
that HIV incidence rates were significantly lower among
continuously incarcerated inmates and treatment
recruited IVDU compared to incidence rates in the
other three populations (Figure 2.) Likewise, the pooled
estimate of HCV incidence density was lowest among
continuously incarcerated inmates (0.75/100py, 95%
CI:0.05,1.44) compared to IVDU recruited through a
combination of treatment programs and street outreach
(13.8/100py, 95%CI:9.48,18.11), and to IVDU
recruited exclusively on the street (20.11/100py, 95%
CI:13.82,26.41) (Figure 3). Finally, the pooled estimate of
HBV incidence density was low among continuously
incarcerated inmates (1.71/100py, 95%CI:1.62,1.80) and
significantly higher in street recruited IVDU (16.06/
100py, 95%CI:15.86,16.25) and all categories of IVDU
combined (16.54/100py, 95%CI:11.71,21.37) (Figure 3).
Inspection of forest plots and I
2 statistics confirmed that
there was a high degree of heterogeneity in incidence rates
of any given infection across populations; and in incidence
of a given infection in a given population across studies
(Figure 2, 3). Results of Egger’s test suggested that publica-
tion bias was present (2-sided P = 0.001).
Meta-regression analyses
After exclusion of sex composition from the list of cov-
ariates (because of marked collinearity with the risk
population variable), the HIV sub-group meta-regression
model explained 52.0% of the variance in pooled inci-
dence of HIV infection. Differences in pooled incidence
of infection were independently associated with risk
population (2-sided P = 0.03), with predominant race
(2-sided P = 0.03), and with person years of follow-up
(2-sided P = 0.03), (data not shown).
In the model, pooled incidence density of infection
was lowest among continuously incarcerated inmates
(0.08/100py) and IVDU populations recruited from
treatment programs (0.98/100py), followed by MSM
(2.12/100py). Higher pooled incidence density of infec-
tion were observed among street recruited IVDU popu-
lations (2.64/100py; based on 17 published estimates),
and inmates who were released and reincarcerated
(2.95/100py; based on 4 published estimates). Pooled
incidence of infection was higher in study samples that
predominantly included African Americans (3.05/100py)
compared to Whites (1.79/100py) and other races
or ethnicities (1.49/100py) (data not shown). Study
design and data quality variables included in the meta-
regression analysis as previously described were not
statistically significant.
Sensitivity analyses
The sensitivity analyses indicated that HIV incidence
results were generally robust to the exclusion of studies
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CIIP
MAIP
IVDU-S
IVDU-T
MSM
All Inmate
All IVDU
All Studies
Study Period n/N Incidence 95%CI Site
1985-n/a 2/1069 0.16 0.02,  0.60 NV
1998 - 2000 0/446  0.00 0.00, 0.43 RI
1985 - 1991 29/865 1.60 1.07, 2.30 CA
1992 -  1996 12/1081  0.60 0.33, 1.11 RI
1994 - 1995 5/104 7.40 2.40, 17.26 CT
2000 - 2009 33/1737 2.22 1.53, 3.11 CA
1988 - 1991 27/5202 0.64 0.42, 0.93 5 cities
1988 - 1991 52/1680 5.49 4.10, 7.19 10 cities
1988 -  1992 83/562 4.80 3.82, 5.94 IL
1988 -  2004 304/1983  2.06 1.83, 2.30 MD
1989 - 1991 13/88 10.70 5.70, 18.30 PA
1992 -  1993 19/671  4.52 2.73, 7.07 MD
1992 - 1996 32 2.18 1.50. 3.09 8 states
1992 - 1996 21 1.04 0.64, 1.59 9 states
1994 -  1995 4/152 4.90 1.34, 12.55 MD
1994 -  1995 7/460 1.10 0.44, 2.27 IL
1994 -  1995 2/250  1.20 0.15, 4.33 NY
1994 -  1995 1/175  1.00 0.03, 5.57 NY
1997 - 1999 0/118 0.00 0.00, 2.27 NY
1997 - 1999 1/123 0.80 0.01, 2.49 NY
1998 -  1999 9/455  0.88 0.401.68 NY
1998 -  1999 23/268  3.37 2.13, 5.05 PR
1982 - 1992 9/98 2.80 1.28, 5.32 CT
1985 - 1990 22/681 1.90 1.19, 2.88 CA
1987 - 1992/3 10/455 0.57 0.27, 1.05 FL
1989 - 1991 6/146 3.00 1.10, 6.53 PA
1990 -  1991 2/177  1.30 0.16, 4.66 NY
1994 - 1997 14/890 0.90 0.74, 2.26 NY
1994 - 1997 7/521 0.90 0.37, 1.91 NJ
1994 - 1997 4/1256 0.20 0.06, 0.58 WA
1994 - 1997 0/733 0.00 0.00, 0.31 CA
1995 -  1998 0/220 0.00 0.00, 1.02 CA
1984 -  1989 94 2.50 2.06, 3.12 MD
1984 -  1989 83 3.20 2.56, 3.98 IL
1984 -  1989 87 2.60 2.06, 3.18 CA
1984 -  1989 104 3.10 2.51, 3.73 PA
1993 -  1995 20/624 2.30 1.40, 3.55 IL
1993 -  1995 17/689 2.00 1.17, 3.20 CO
1993 -  1995 22/662 2.70 1.69, 4.09 CA
1993 -  1995 14/545 2.90 1.59, 4.87 NY
1995 - n/a 5/523 1.30 0.42, 3.03 WA
1995 -  1997 24/745 2.26 1.45, 3.36 MA
1995 -  1997 7/551 0.88 0.35, 1.81 NY
1995 -  1997 14/573 1.70 0.93, 2.85 CA
1995 -  1997 6/312 1.31 0.48, 2.85 CO
1995 -  1997 4/264 1.09 0.30, 2.79 IL
1995 -  1997 17/635 1.85 1.08, 2.96 WA
1999 - 2006 24/729 1.22 0.78, 1.81 MA
1999 - 2006 49/624 2.78 2.05, 3.67 IL
1999 - 2006 35/726 1.67 1.17, 2.34 CO
1999 - 2006 57/737 2.80 2.12, 3.63 NY
1999 - 2006 53/736 2.50 1.87, 3.27 CA
1999 - 2006 41/743 1.81 1.30, 2.46 WA
I
2 = 99.9, Ȥ
2 = 0.00 0.08 0.00, 0.24
I
2 = 99.9, Ȥ
2 = 0.00 2.92 2.02, 3.82
I
2 = 99.9, Ȥ
2 = 0.00 2.78 2.24, 3.32
I
2 = 99.9, Ȥ
2 = 0.00 1.14 0.83, 1.45
I
2 = 99.9, Ȥ
2 = 0.00 2.12 1.82, 2.42
I
2 = 99.9, Ȥ
2 = 0.00 1.93 1.41, 2.86
I
2 = 99.9, Ȥ
2 = 0.00 2.15 1.80, 2.49
I
2 = 99.9, Ȥ
2= 0.00 2.12 1.84, 2.40
IRAR
Figure 2 Meta-analyses of HIV incidence studies. 95%CI, 95% confidence interval; I
2,I
2 statistic; c
2, chi-squared statistic.
aEstimated from
cumulative incidence (cumulative incidence = 1-exp(incidence density × time)). White square: CIIP, continuously incarcerated inmate population;
White triangle: IRAR, inmates released and reincarcerated; Black square: IVDU-S, intravenous drug users recruited through street outreach; Black
vertical bar: IVDU-T, intravenous drug users recruited from drug treatment programs or clinics; White disk: MSM, men who have sex with men;
Black diamond: Random effects meta-analysis. Multiple data points from a single study denote incidence estimates from different recruitment
sites in multisite studies.
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Page 7 of 14discarded from consideration in the main meta-analysis.
When excluded articles were included in the analysis
[4-44,46,47,57,58,92-94], all pooled estimates of HIV
incidence remained within 8.0% of the main meta-analy-
sis results, with a few exceptions. Pooled HIV incidence
rates increased for treatment recruited IVDU, (3.31/
100py; 95%CI:3.0,3.6), and for all IVDU, (3.06/100py;
95%CI:2.7,3.4), when two of the studies that inferred
HIV incidence based on self-reported date of last sero-
negative test were included [55,56]. These estimates
were 2.9 and 1.4 times greater than the estimates from
the main analysis for these risk groups. Likewise, pooled
HIV incidence rates increased for MSM, (3.45/100py;
95%CI: 3.1,3.8), when two retrospective studies that
used stored specimens from routine testing of MSM
with primary or secondary syphilis at STD clinics were
included [95,96]. This estimate was 1.6 times greater
than the estimate from the main analysis for MSM.
Discussion
Fueled by reports of HIV and STI outbreaks in correc-
tional facilities in the US [11,50,97-101] and in other
high-income countries (Scotland [102,103], Australia
[17]), the debate about the magnitude of inmate-to-
inmate transmission of HIV in the US has spanned more
than two decades. The pattern of results that emerged
from our comprehensive review and meta-analysis of
HIV, HCV, and HBV incidence studies support the
0.00 20.00 40.00 60.00
vlahov, 1993
macalino, 2004
garfein, 1998
hagan, 2004
villano, 1997
thorpe, 2002
des jarlais, 2003
des jarlais, 2003
hahn, 2002
fuller, 2004
CIIP
IVDU-S/T
IVDU-S
All IVDU
All Studies
Study Period n/N Incidence 95%CI Site
1985 - 1987 2/164 1.10 0.13, 3.97 MD
1998 - 2000 2/446 0.40 0.04, 1.31 RI
1994 - 1996 13/105 16.00 8.55, 27.44 MD
1994 - 2001 134/484 11.60 9.74, 13.76 WA
1988 - 1996 43/142 6.40 4.63, 8.62 MD
1997 - 1999 29/353 10.00 6.70, 14.36 IL
1997 - 1999 19/76 34.00 20.43, 52.98 NY
1997 - 1999 6/65 9.30 3.40, 20.15 NY
2000 - 2001 48/195 25.10 18.53, 33.32 CA
2000 - 2003 13/62 35.90 19.07, 61.24 NY
I
2 = 99.9, Ȥ
2 < 0.001 0.75 0.05, 1.44
I
2 = 99.9, Ȥ
2 < 0.001 13.80 9.48, 18.11
I
2 = 99.9, Ȥ
2 < 0.001 20.11 13.82, 26.41
I
2 = 99.9, Ȥ
2 < 0.001 18.53 14.71, 22.35
I
2 = 99.9, Ȥ
2 < 0.001 14.97 11.31, 18.62
A)
Study Period n/N Incidence 95%CI Site
1998 - 2000 15/446 2.70 1.49, 4.38 RI
2000 - 2001 18/503 1.28
a 0.76, 2.02 GA
1988 - 1992 75/240 14.19 11.16, 17.79 MD
1997 - 1999 21/90 30.70 19.00, 46.93 NY
1997 - 1999 11/92 12.20 6.10, 21.87 NY
1994 - 1996 46/460 9.10 6.65, 12.12 WA
I
2 = 99.9, Ȥ
2 < 0.001 1.71 1.62, 1.80
I
2 = 99.9, Ȥ
2 < 0.001 16.06 15.86, 16.25
I
2 = 99.9, Ȥ
2 < 0.001 16.54 11.71, 21.37
I
2 = 99.9, Ȥ
2 < 0.001 11.69 7.93, 15.44
0.00 20.00 40.00 60.00
macalino, 2004
khan, 2005
levine, 1996
des jarlais, 2003
des jarlais, 2003
hagan, 1999
CIIP
IVDU-S
All IVDU
All Studies
B)
Figure 3 Meta-analyses of A) HCV Incidence Studies and B) HBV Incidence Studies. 95%CI, 95% confidence interval; I
2,I
2 statistic; c
2,
chi-squared statistic.
aEstimated from cumulative incidence (cumulative incidence = 1 - exp(-incidence density × time)). White square: CIIP,
continuously incarcerated inmate population; White triangle: IVDUS/T, intravenous drug users recruited through either street outreach or from
drug treatment programs or clinics; Black square: IVDU-S, intravenous drug users recruited through street outreach; White disk: MSM, men who
have sex with men; Black diamond: Random effects meta-analysis. Multiple data points from a single study denote incidence estimates from
different recruitment sites in multisite studies.
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Page 8 of 14notion that the transmission of HIV and other blood-
borne infections in US correctional populations occurs at
alarmingly high rates during the periods that recidivists
spend outside prison. In our study, HIV incidence among
inmates released and reincarcerated was much greater
(2.92/100py) than in the US general population (0.02 per
100 population in 2006) [104], while HIV incidence
among inmates continuously incarcerated was more
similar to the general populace (0.08/100py). Rates of
HIV seroconversion among reincarcerated inmates were
comparable to those typically observed among non-incar-
cerated individuals who engage in high-risk injecting and
sexual behaviors (street-recruited IVDU, 2.78/100py;
MSM, 2.12/100py). HIV incidence among IVDU enrolled
in a drug treatment program (1.14/100py) laid between
the lower bound observed in the general population and
the higher bound observed in the high-risk groups. In
contrast, intraprison incidences of HCV (0.75/100py) and
HBV (1.71/100py) infection were also higher than in the
US general population (0.01 and 0.02 per 100 population,
respectively, in 2006) [105], but several-fold lower than
among non-incarcerated IVDU (HCV, 18.53/100py;
HBV, 16.54/100py) and MSM (HCV, no data available;
HBV, 15.9%) [51]. The greater incidence of these infec-
tions compared with HIV probably reflects the higher
prevalence rates of HCV and HBV infection among
prison entrants [106] and higher infectivity of HCV and
HBV compared with HIV [107,108].
Despite significant heterogeneity among included stu-
dies, our results were consistent across meta-analyses
and multiple meta-regression analyses. Sensitivity ana-
lyses indicated that results were only sensitive to the
exclusion of four studies, two in which incidence was
inferred from self reported data [55,56], and two in
which MSM with early syphilis infection were tested ret-
rospectively [95,96]. Furthermore, our summary
estimates of HIV incidence among inmates were compar-
able with estimates that were published before 1990
[109-112]; did not report data in the desired format [48];
and with studies conducted in Europe [113-115].
Low incidence rates of HIV transmission in prison
(range, 0.0 to 0.4/100py) have been reported in three US
studies published in the late 1980s [109-111]. The extent
to which these older studies further our understanding
of the current dynamic of HIV transmission in prison is
unclear, since HIV prevalence at prison intake was con-
siderably lower in the 1980s compared with the 2000s.
Of note however, study start year and publication year
did not significantly contribute to the meta-regression
analysis model, suggesting that calendar time was not an
important source of heterogeneity among HIV studies.
Also, in a US-based study that did not provide annual-
ized incidence density estimates of HIV infection, but
retrospectively followed 5,265 male inmates from their
entry into custody in 1978 until 2000, 0.63% of the
detainees were diagnosed with HIV infection during
incarceration and 4.6% after release from prison [48].
Bias may have inflated the difference in incidence during
the incarceration and released periods in this study, but
no other source of information was found that estimated
HIV incidence among inmates released from a US
prison as compared to inmates undergoing periods of
continuous incarceration.
In three European studies, HIV incidence among
detainees ranged between 0 and 1.0/100py [113-115],
and was highest among male and female IVDUs
recruited in 1987-1988 at a prison remand centre in
Sweden (the authors of these studies did not clearly
indicate what percentage of inmates had been continu-
ously incarcerated) [115]. In a small Australian study (n
= 90), including inmates of both genders, a higher inci-
dence of HCV seroconversion was found among inmates
who underwent a period of release before reincarcera-
tion compared with inmates who had been continuously
incarcerated (10.8 vs. 4.5/100py; P = 0.07) [116].
Although the results from these developed nations and
from the US seem to be consistent in their documenta-
tion of low HIV incidence rates within the prison sys-
tem and higher rates during post release, international
comparisons should be made with great caution given
the differences in correctional systems and epidemiolo-
gical contexts across countries [117]. Hence, two studies
identified from the developing world reported higher
HIV incidence rates - Brazil (2.8/100py) [118] and Thai-
land (4.18/100py) [16]. It is clear that an important gap
still exists in our understanding of HIV and blood-borne
i n f e c t i o nt r a n s m i s s i o ni nc o r r e c t i o n a le n v i r o n m e n t s
throughout the world.
Among MSM, our pooled estimate of HIV incidence
is similar to that calculated in a recent study which used
a fixed-effects model to calculate a weighted average
(2.39%) [119]. In another study, estimates calculated for
MSM (0.7/100py) and IVDU (1.5/100/py) differed in
comparison to our pooled estimates [120], but this cita-
tion [120] did not use meta-analysis methods to esti-
mate HIV incidence in these risk groups.
Our findings are consistent with studies of risky beha-
viors in correctional populations and hypotheses pro-
posed to explain the apparent paradox of low incidences
of HIV, HBV and HCV in the prison system, and high
incidence of HIV, HBV and HCV during the post-
release periods. As mentioned earlier, the US correc-
tional system offers conditions seemingly favorable to
the transmission of blood-borne viruses. There is a large
reservoir of potential transmitters in the prison system
at any time, and many inmates engage in sexual and
drug-mediated risk behaviors regardless of the general
lack of condoms [49,50] and sterile injection material
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Page 9 of 14[10,48]. For instance, although the frequency of drug use
in prison is typically lower than in the general commu-
nity [48,113,121], there is clear evidence that incarcer-
ated drug users often continue to inject; that injecting
equipment is frequently shared among inmates; and that
the risk of equipment contamination by parenterally-
transmitted viruses is higher within the prison system
than outside of it [20,113].
Thus, a possible explanation for the low transmission
of HIV, HCV, and HBV within the prison system is that
inmates’ risk networks are on average considerably
smaller and more closed within correctional facilities
than in the community. Given the de facto segregation
of detainees by age, sex, race, category of offense and,
historically in some states, by HIV status [10], it is plau-
sible that the lack of bridges between intra-prison net-
works, and the small size of the networks, lead to the
rapid saturation of the susceptible inmates who have
effective contacts with a transmitter [106]. However, the
formation of bridges between inmates’ risk networks
when an adequate proportion of susceptible inmates
exists may lead to efficient infection transmission
[52,99]. In contrast, studies have shown that many
inmates, following re-entry in the community, revert to
pre-incarceration habits and engage in high rates of
unsafe sexual and intravenous drug use behaviors
[122-126], as suggested, for instance, by high frequency
of anal sex reporting [124], excess occurrence of drug
overdose [125-127], and high risk for mortality
[80,128-130] at post release. Among the four studies on
inmates released and reincarcerated, those reporting the
highest post-release incidence rates followed recidivist
female IVDU [34] and recidivist MSM [36]. As such,
sub-populations of inmates with risky pre-incarceration
behaviors may be at particularly high risk during periods
between release and reincarceration.
There was a notable difference in the reported propor-
tion of IVDU and MSM in recidivist inmate populations
[34,36,53,62] as compared to continuous inmates
[34,35,60,83]. Three of the four recidivist studies
reported the proportion of IVDU (59.1% and 100%) or
MSM (0.0% and 100%); while two continuous inmate
studies reported the proportion of IVDU (2.9% and
11%) or MSM (0.0% and 4.5%) (Additional file 2). These
data suggest that the proportion of IVDU and MSM
might be larger in recidivist studies than in continuous
inmate studies. If real, such a difference would be
another explanation for the observed differences in inci-
dence among the studies in continuous inmates, recidi-
vists and community-living populations.
A meta-analysis of pooled incidence rates stratified by
risk behaviors would have further clarified whether the
recidivist groups are at increased risk of infection com-
pared to their continuous inmate or community living
counterparts. However, available data were not sufficient
for this type of analysis. Only one study reported the
incidence of HBV (8.2/100py) and HCV (5.5/100py)
among continuously incarcerated inmates who reported
injection drug use [60]. For both infections, the inci-
dence in this group of inmates was greater than the
pooled estimate for CIIP cohorts, but was lower than
the pooled estimate for community IVDU; the study did
not report whether injection drug use occurred during
or prior to incarceration.
Our study is subject to limitations. Despite the crucial
importance of characterizing the relations between
incarceration and the HIV epidemic in the US, we
found only five incidence studies published between
1990 and 2004, and one published between 2005 and
2009, that reported primary data on the transmission of
HIV in US correctional populations. The recent litera-
ture on incidence of blood-borne infections among
MSM was also sparse. The importance of further studies
on these outcomes in these populations cannot be over
emphasized. Our observation of high infection rates
among inmates who were released and reincarcerated
was based on four studies only and incidence of HIV
was relatively low in two of these studies (Figure 2).
Three studies evaluated predominantly IVDU women
only; one evaluated MSM only; none measured HBV
and HCV incidence; and none included inmates who
were not reincarcerated after their release.
In the random effects analysis, the limited number of
studies that assessed incidence of HIV, HBV or HCV
infection made it difficult to disaggregate the sources of
heterogeneity across studies. Several studies lacked data
for inclusion in the meta-regression models and, in gen-
eral, data were insufficient to properly evaluate the
influence of key cofactors, such as sex, age, race, and
interaction between population and proportions of sub-
jects engaging in risk behaviors. Other unmeasured fac-
tors may also have contributed to the observed
heterogeneity.
Egger’s test suggested that publication bias might have
affected our results. Possible sources of publication bias
include citation bias, poor methodological quality of
smaller studies, and true heterogeneity. Although study
selection criteria were clearly defined and study selec-
tion was done by two independent reviewers, we cannot
entirely exclude the possibility that some studies were
missed due to low citation frequency. Most reviewed
studies, in particular small studies, shared one or several
important methodological shortcomings, including pur-
posive or convenience samples, inconsistent operational
definition of risk populations, short follow-up times,
high attrition rates, and inappropriate periods of risk
assessment. As already indicated, there was significant
heterogeneity across included studies, part of which is
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Page 10 of 14likely to have been true heterogeneity. Finally, Egger’s
test can be sensitive to extreme observations and large
sample size, both of which were present in this meta-
analysis.
Conclusion
Our findings support the notion that comprehensive stra-
tegies are needed to control the spread of parenterally and
sexually transmitted viruses in US correctional popula-
tions. Examples are prevention programs to reduce trans-
mission within prison systems [129]; transition programs
to better prepare inmates for life after discharge; and inter-
ventions to ensure continuity of care in the community.
While incarceration does not appear to increase the risk
for HIV or other blood-borne disease infection for the
average inmate, and while rates of transmission in US cor-
rectional settings appear to be lower than would be
expected outside prison or jail, the lack of sufficient data
for meta-regression and sub-group analyses made it diffi-
cult to draw definitive conclusions about the increased
risk incarceration poses on high risk groups such as MSM
and IVDU, or about the increased risk to these groups and
the community during periods of release. In addition to
supporting innovative intervention studies, our findings
also point to the need for further research to update our
understanding of the transmission of blood-borne and
sexually-transmitted infections in inmate populations, and,
most importantly, to clarify the role of the post release
period in infection risk and further spread to the general
community. The consistency of our results across infec-
tious agents confirms that HBV and HCV infections may
be used as sentinel indicators of risk for HIV infection in
correctional settings.
Additional material
Additional file 1: “HIV, HBV and HCV incidence studies”.
Additional file 2: “HIV, HBV and HCV studies by infection and risk
group”.
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